Search results
Results from the WOW.Com Content Network
Methylchloroisothiazolinone, also referred to as MCI, is the organic compound with the formula S(C 2 HCl)C(O)N(CH 3).It is a white solid that melts near room temperature. The compound is an isothiazolinone, a class of heterocycles used as biocides.
Chloromethylisothiazolinone (CMIT) and 2-methyl-4-isothiazolin-3-one (methylisothiazolinone or MIT) are popular derivatives. A 3:1 mixture of CMIT:MIT is sold as Kathon. Kathon is supplied as a concentrated stock solution containing from 1.5 to 15% of CMIT/MIT. For applications the recommended use level is from 6 ppm to 75 ppm active ...
In the United States, the Environmental Protection Agency has a 1998 data sheet on methylisothiazolinone in their Pesticides section [13] which reads in part "Human Health Assessment: Toxicity: In studies using laboratory animals, methylisothiazolinone has been shown to be of moderate acute toxicity by the oral and inhalation routes. It is ...
Although no treatment options have been proven to help manage 3-Methylcrotonyl-CoA carboxylase deficiency [9] proposed treatments include L-carnitine supplements, [10] glycine administration, [11] biotin supplements [4] and dietary restriction of leucine.
Usage of incompatible levels of antimicrobials provides the selective pressure that has driven the direction and evolution of resistance of bacterial pathogens. [19] This has been seen at sub-MIC levels of antibiotics. [20] As such, it is increasingly important to determine the MIC in order to make the best choice in prescribing antimicrobials.
For most substances presented, the optimal levels are the ones normally found in the population as well. More specifically, optimal levels are generally close to a central tendency of the values found in the population. However, usual and optimal levels may differ substantially, most notably among vitamins and blood lipids, so these tables give ...
Methylenetetrahydrofolate reductase deficiency is the most common genetic cause of elevated serum levels of homocysteine (hyperhomocysteinemia). It is caused by genetic defects in MTHFR, which is an important enzyme in the methyl cycle. [1] Common variants of MTHFR deficiency are asymptomatic and have only minor effects on disease risk. [2]
COMT inhibitors are indicated for the treatment of Parkinson's disease in combination with levodopa and an aromatic L-amino acid decarboxylase inhibitor (e.g. carbidopa or benserazide). The therapeutic benefit of using a COMT inhibitor is based on its ability to prevent the methylation of levodopa to 3- O -methyldopa , thus increasing the ...